Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

· Issued by Mirum Pharmaceuticals, Inc.

On 6ix: 6ix.com/news/mirum-pharmaceuticals-announces-positive-results-from-cohort-2-of-the-pivotal-progress-study-of-atebrioztm-zilurgisertib-in-pediatric-patients-aged-6-to-less12-years-with-fibrodysplasia-ossificans-progressiva-1

Watch Mirum Pharmaceuticals' latest callMirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Mirum Pharmaceuticals (NASDAQ:MIRM) Q2 2026 Earnings Call
Mirum Pharmaceuticals' next earnings callMirum Pharmaceuticals (NASDAQ:MIRM) Q3 2026 Earnings Call · Nov 3, 2026 at 4:30 PM ESTRegister

- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions

- Mirum plans to submit an sNDA in H1 2027 to expand the ATEBRIOZ indication to pediatric patients aged 6 to

Mirum Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Mirum Pharmaceuticals

Later from Mirum Pharmaceuticals

All Mirum Pharmaceuticals news releases